Business Wire

Masimo and MS Westfalia GmbH (MSW) Expand Partnership to Add Masimo SedLine® Brain Function Monitoring, O3® Regional Oximetry, and Oxygen Reserve Index (ORi™) to the MSW Modular Point-of-Care Hybrid Jenny

Share

Masimo (NASDAQ: MASI) and MS Westfalia GmbH (MSW) announced today that MSW will integrate additional Masimo measurement technologies into MSW’s plug-and-play hybrid Jenny platform, to help clinicians assess brain function, oxygenation, ventilation, and resuscitation status.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200225005103/en/

After launching the Jenny modular point-of-care monitoring device with integrated Masimo noninvasive, continuous rainbow SET® measurements (including total hemoglobin, SpHb®) and Masimo sidestream and mainstream NomoLine® capnography, MSW plans to add Masimo Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and Oxygen Reserve Index (ORi™) to Jenny. By doing so, MSW will make the platform an even more versatile and comprehensive monitoring solution, suitable for use in a variety of care areas, including the ICU and the OR, as well as in EMS and military settings.

The three additional technologies, currently available directly from Masimo on the Root® Patient Monitoring and Connectivity Platform, are:

  • Next Generation SedLine Brain Function Monitoring, which assists clinicians in monitoring the state of the brain under anesthesia, with bilateral data acquisition and processing of EEG signals and an enhanced Patient State Index (PSi).
  • O3 Regional Oximetry, which may help clinicians monitor cerebral oxygenation in situations in which pulse oximetry alone may not be fully indicative of the oxygen in the brain.
  • ORi, the first noninvasive and continuous parameter to provide insight into the oxygen reserve of patients receiving supplemental oxygen.

Eugen Kagan, CEO of MSW, said, “Our company’s mission is to save lives and improve quality of life for our patients. For more than 25 years, our goal has been to develop products that assist healthcare providers in the hospital and pre-hospital markets by helping to improve patient outcomes and increase patient satisfaction and workflow efficiency – while lowering the cost of healthcare. We accomplish this by developing revolutionary approaches to new product development and by partnering with best-in-class partners like Masimo so we may meet the needs of a constantly changing healthcare landscape. The expanded technology partnership between MSW and Masimo allows us to offer our customers the most innovative technologies, helping them overcome many of the daily challenges they face in healthcare delivery.”

Joe Kiani, Founder and CEO of Masimo, said, “It’s great to see MSW’s commitment to incorporating our full suite of noninvasive, continuous measurements into their all-in-one modular Jenny platform. We are happy to be able to help MSW accomplish its wonderful mission.”

ORi has obtained CE marking and is not available in the U.S.

@MasimoInnovates | #Masimo

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve patient outcomes and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.1 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,2 improve CCHD screening in newborns,3 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.4-6 Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world,7 and is the primary pulse oximetry at 9 of the top 10 hospitals according to the 2019-20 U.S. News and World Report Best Hospitals Honor Roll.8 Masimo continues to refine SET® and in 2018, announced that SpO2 accuracy on RD SET® sensors during conditions of motion has been significantly improved, providing clinicians with even greater confidence that the SpO2 values they rely on accurately reflect a patient’s physiological status. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7® and Radius PPG™, portable devices like Rad-67™, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97®. Masimo hospital automation and connectivity solutions are centered around the Iris® platform, and include Iris Gateway®, Patient SafetyNet, Replica™, Halo ION™, UniView™, and Doctella™. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/.

ORi and RPVi have not received FDA 510(k) clearance and are not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

References

  1. Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
  2. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
  3. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
  4. Taenzer AH et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
  5. Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
  6. McGrath SP et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
  7. Estimate: Masimo data on file.
  8. http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.

About MSW

MS Westfalia GmbH is one of the largest distributors of medical equipment on the market in Central Europe and the CIS. The company was founded in 1995. Since then, successful business allowed the company not only to develop the promotion of world famous brands, but also to begin its own production of high-tech medical devices.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo SedLine®, O3®, ORi™, rainbow SET®, NomoLine®, and Root®. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo SedLine, O3, ORi, rainbow SET, and NomoLine, and Root, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Contact information

Media Contacts:
Masimo
Evan Lamb
949-396-3376
elamb@masimo.com

MSW
Julia Artel
+49 2241 944 933
j.artel@mswestfalia.de

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Nike Extends its Athletic Leadership5.2.2020 19:00:00 CETPress release

Today, NIKE, Inc. (NYSE: NKE), unveiled breakthrough innovation for athletes competing in the Tokyo 2020 Games, including footwear designed to provide runners with a measurable performance benefit for a new era of competition. The NEXT% platform, introduced by barrier-breaking marathoner Eliud Kipchoge, will now expand into new disciplines following its unparalleled success in distance running. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200205005708/en/ An international group of athletes joined the Nike 2020 Forum in New York to unveil the brand's latest performance and sustainable innovations. From left to right: Ibtihaj Muhammad, English Gardner, Leticia Bufoni, Blake Leeper, Timothy Cheruiyot, Dina Asher-Smith, Tomoya Ochiai, Sky Brown, Chris Mosier, Nyjah Huston, DeAnna Price, Bebe Vio, Kevin Mayer, Megan Blunk, Brandi Chastain, Aaron Brown, Sophie Hahn, Aori Nishimura, Diana Taurasi, Miles Chamley-Watson, Leon Schae

Cepton Expands With $50 Million Investment From Koito5.2.2020 18:00:00 CETPress release

Cepton Technologies, Inc., a leading provider of state-of-the-art, intelligent, lidar-based solutions, announced today that it has raised over $50 million in Series C funding. This brings Cepton’s total funding to nearly $100 million, providing a strong foundation to substantially ramp up its R&D efforts, expand its footprint in the automotive market and support major customers worldwide. The latest funding round was led by Koito Manufacturing Co., Ltd. (TYO:7276), the automotive Tier 1 and world-leading provider of automotive lighting systems, with an investment of $50 million. Existing investors in Cepton also participated in this round. As part of the transaction, Koito will obtain non-exclusive rights to manufacture and sell Cepton’s lidar sensor design for an automotive application, using key components supplied by Cepton. Cepton will use the proceeds to accelerate development and deployment of its advanced lidar technology in ADAS applications, in autonomous vehicle applications,

Imricor Announces First Cases Successfully Performed at Heart Center Dresden5.2.2020 17:40:00 CETPress release

Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) is pleased to announce the first procedures using the Company’s products following CE mark of the Vision-MR Ablation Catheter have been performed at the Heart Center Dresden. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200205005672/en/ Drs. Christopher Piorkowski (left) and Thomas Gaspar (right) performing iCMR ablations at the Heart Center Dresden (Photo: Heart Center Dresden). Three procedures were successfully performed over two days by Dr. Christopher Piorkowski and Dr. Thomas Gaspar (https://www.herzzentrum-dresden.com/rhythmologie/unser-team/). Additional physicians at the Heart Center Dresden will also begin performing procedures immediately. These procedures mark the first iCMR ablations anywhere in the world to ever be performed outside of a clinical trial. They were performed in an iCMR lab fitted with a Siemens 1.5T MAGNETOM Aera MR scanner. “It’s ano

VALBIOTIS Announces a Global Strategic Partnership With NESTLÉ HEALTH SCIENCE For the Development and Commercialization of TOTUM-63, a Plant-derived Active Substance With Clinically Demonstrated Metabolic Health Benefits on Prediabetics5.2.2020 17:30:00 CETPress release

Regulatory News: VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/SME eligible ), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the signature of a global long-term strategic partnership with Nestlé Health Science for the development and commercialization of TOTUM-63, an innovative and patented combination of 5 plant extracts specifically designed to reduce the risk of developing Type 2 Diabetes on prediabetics. Sébastien PELTIER, CEO of VALBIOTIS states: “Nestlé Health Science is an ideal strategic partner for VALBIOTIS. Its global reach, strategic intent to develop science-based nutritional health solutions and focus on fighting metabolic disorders like diabetes will be instrumental to TOTUM-63's worldwide commercialization success. We are excited about the opportunity that this deal brings to VALBIOTIS and to the many millions of people around the world at risk of becoming Type 2 diabetics. This trans

Skilling lanserar branschens första sömlösa integration med Spotwares cTrader, inriktad på erfarna handlare.30.1.2020 08:00:00 CETPress release

Forex- och CFD-handelsplattformen Skilling annonserade förra veckan lanseringen av branschens första sömlösa integration med Spotwares cTrader - en unik funktion som internt kallas Ett konto. Två plattformar. Detta pressmeddelande använder multimedia. Se den fullständiga versionen här: https://www.businesswire.com/news/home/20200130005070/sv/ Skilling lanserar branschens första sömlösa integration med Spotwares cTrader. (Photo: Business Wire) Funktionen gör att Skilling kan erbjuda sina kunder sömlös handel över två olika handelsplattformar på ett enda Skilling-konto utan att behöva finansiera och hantera två olika konton separat. ”Enkelt uttryckt ville vi ge våra kunder valet vilken handelsplattform de kan använda - vår egen Skilling Trader eller en mer avancerad klientorienterad cTrader. Problemet du har med andra mäklare som erbjuder flera plattformar är behovet av att finansiera två konton separat, upprätthålla sunda marginaler på två olika konton och också ha två uppsättningar av

inRiver utser Per-Olof Schroeder till ny VD29.1.2020 16:43:00 CETPress release

inRiver, som levererar SaaS-baserade lösningar för Product Information Management (PIM), meddelar att styrelsen idag har utsett Per-Olof Schroeder till ny VD för bolaget. Per-Olof tillträder sin tjänst med omedelbar verkan. “Styrelsen tackar Thor Johnson för hans ledning av bolaget under de två senaste åren, och är glada över att välkomna Per-Olof som vår nye VD," säger inRivers styrelseordförande, Jorgen Smidt. "Per-Olof har en påvisad erfarenhet av att mycket framgångsrikt leda utveckling av SaaS Computing Services, molnbaserade tjänster, och samtidigt leverera stark tillväxt både gällande intäkter, lönsamhet och marknadsandelar. I sin roll som bolagets VD kommer han fortsätta att utveckla inRivers mission att hjälpa våra kunder bli bäst på att marknadsföra och sälja sina produkter." Schroeder har mer än 25 års erfarenhet av ledande befattningar inom IT-branchen, inklusive 15 år på Microsoft, varav sju år som chef över Microsofts Productivity & Business Process Business Group i väste

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom